Use of processing aides not intended for pharmaceutical use in sterile drug production.
Inspection Record
New Vitalis Pharmacy LLC — FDA 483 Findings
Inspectors Ucheabuchi C Chudi-NwankworThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Use of a sporicidal agent in the facility's ISO 5 areas and classified areas was lacking.
Personnel were observed conducting aseptic manipulations where the movement of "first air" in the ISO 5 area is blocked or disrupted.
Failure to conduct post-use filter-integrity testing on filters used to sterilize drug products.
Smoke studies were inadequately performed under dynamic conditions.
HEP A filters are not sealed around the perimeter.
Use of a disinfectant in a manner insufficient to achieve adequate levels of disinfection.
Use of non-sterile cleaning wipes in the ISO 5 area.
Personnel infrequently sanitized gloves to prevent contamination.
The facility design was observed to allow the influx of lesser quality air into a classified area containing higher quality air.
About this record
Extracted automatically from the document US FDA published on 2023-11-01. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
